These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 29423787)

  • 61. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
    Sturt AS; Dokubo EK; Sint TT
    Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Lipid Abnormalities and Inflammation in HIV Inflection.
    Funderburg NT; Mehta NN
    Curr HIV/AIDS Rep; 2016 Aug; 13(4):218-25. PubMed ID: 27245605
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The role of statins in managing diabetic dyslipidemia.
    Toth PP
    J Fam Pract; 2010 May; 59(5 Suppl):S23-9. PubMed ID: 20544054
    [TBL] [Abstract][Full Text] [Related]  

  • 64. DemographIc Assessment and EValuation of DEgree of Lipid Control in High Risk Indian DySlipidemia PatiEnts (DIVERSE Study).
    Malhotra N; Keshan MK; Agarwal A; Kumar RA; Trailokya A; Dalvi K; Talele S
    J Assoc Physicians India; 2016 Apr; 64(4):38-46. PubMed ID: 27734640
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cardiovascular risk and dyslipidemia management in HIV-infected patients.
    Stein JH
    Top Antivir Med; 2012; 20(4):129-33; quiz 123-4. PubMed ID: 23154252
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Evaluation and pharmacologic management of the HIV-infected patient with dyslipidemia.
    Hardwicke RL; Lewis ST; Grimes RM
    J Assoc Nurses AIDS Care; 2010; 21(5):429-38. PubMed ID: 20303794
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Maintenance of statin therapy among people living with HIV.
    Boettiger DC; Kerr S; Chattranukulchai P; Siwamogsatham S; Avihingsanon A
    AIDS; 2021 Mar; 35(4):567-574. PubMed ID: 33252492
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Lipidome Abnormalities and Cardiovascular Disease Risk in HIV Infection.
    Bowman E; Funderburg NT
    Curr HIV/AIDS Rep; 2019 Jun; 16(3):214-223. PubMed ID: 30993515
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Attenuated T-lymphocyte response to HIV therapy in individuals receiving HMG-CoA reductase inhibitors.
    Narayan S; Hawley N; Giguère P; Badley AD
    HIV Clin Trials; 2003; 4(3):164-9. PubMed ID: 12815556
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins.
    Negredo E; Moltó J; Puig J; Cinquegrana D; Bonjoch A; Pérez-Alvarez N; López-Blázquez R; Blanco A; Clotet B; Rey-Joly C
    AIDS; 2006 Nov; 20(17):2159-64. PubMed ID: 17086055
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients.
    Jiménez-Nácher I; Alvarez E; Morello J; Rodriguez-Nóvoa S; de Andrés S; Soriano V
    Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):457-77. PubMed ID: 21342079
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Rhabdomyolysis in an HIV-infected patient with impaired renal function concomitantly treated with rosuvastatin and lopinavir/ritonavir.
    de Kanter CT; Keuter M; van der Lee MJ; Koopmans PP; Burger DM
    Antivir Ther; 2011; 16(3):435-7. PubMed ID: 21555828
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [GeSIDA/National AIDS Plan: Consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (Updated January 2014)].
    ;
    Enferm Infecc Microbiol Clin; 2014; 32(7):446.e1-42. PubMed ID: 24953253
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Rosuvastatin slows progression of subclinical atherosclerosis in patients with treated HIV infection.
    Longenecker CT; Sattar A; Gilkeson R; McComsey GA
    AIDS; 2016 Sep; 30(14):2195-203. PubMed ID: 27203715
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Triad of the Ischemic Cardiovascular Disease in People Living with HIV? Association Between Risk Factors, HIV Infection, and Use of Antiretroviral Therapy.
    Zanetti HR; Mendes EL; Palandri Chagas AC; Gomes Douglas MO; Paranhos Lopes LT; Roever L; Gonçalves A; Santos Resende E
    Curr Atheroscler Rep; 2018 May; 20(6):30. PubMed ID: 29777448
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Leveraging a Landmark Trial of Primary Cardiovascular Disease Prevention in Human Immunodeficiency Virus: Introduction From the REPRIEVE Coprincipal Investigators.
    Grinspoon SK; Douglas PS; Hoffmann U; Ribaudo HJ
    J Infect Dis; 2020 Jul; 222(Suppl 1):S1-S7. PubMed ID: 32645161
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Statin effect on coronary calcium distribution, mass and volume scores and associations with immune activation among HIV+ persons on antiretroviral therapy.
    Lipinski J; Margevicius S; Schluchter MD; Wilson DL; McComsey GA; Longenecker CT
    Antivir Ther; 2020; 25(8):419-427. PubMed ID: 33901017
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The Evolving Landscape of ASCVD Risk Among Patients With HIV.
    Malvestutto C
    J Fam Pract; 2022 Jul; 71(6 Suppl):S58-S62. PubMed ID: 35960946
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Statins for primary cardiovascular disease prevention among people with HIV: emergent directions.
    Fitch KV; Fulda ES; Grinspoon SK
    Curr Opin HIV AIDS; 2022 Sep; 17(5):293-300. PubMed ID: 35938463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.